Epigenetic information and estrogen receptor alpha expression in breast cancer

Oncologist

Volumn 11, Issue 1, 2006, Pages 1-8

  Giacinti, Laura ^a,b   Claudio, Pier Paolo ^a   Lopez, Massimo ^b   Giordano, Antonio ^a,c,d  

^a Temple University   (United States)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c Laboratory of Biomedical Technology and Oncology   (Italy)

^d TEMPLE UNIVERSITY   (United States)

Author keywords

Anticancer drug combinations; Breast cancer; Estrogen receptors; Gene expression regulation

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; DNA METHYLTRANSFERASE; DNA TOPOISOMERASE INHIBITOR; ESTROGEN RECEPTOR ALPHA; HISTONE DEACETYLASE INHIBITOR; METHYLTRANSFERASE INHIBITOR; TAMOXIFEN; TRICHOSTATIN A; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; BREAST CARCINOGENESIS; CANCER HORMONE THERAPY; DNA METHYLATION; DRUG DESIGN; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; EPIGENETICS; GENE EXPRESSION REGULATION; GENE REPRESSION; HUMAN; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN EXPRESSION; REVIEW; TRANSCRIPTION REGULATION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DNA METHYLATION; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE SILENCING; HISTONE DEACETYLASES; HUMANS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 31444449552     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.11-1-1     Document Type: Review

References (71)

1. Shao W, Brown M. Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy. Breast Cancer Res 2004;6:39-52.
2. Lapidus RG, Nass SJ, Davidson NE. The loss of estrogen and progesterone receptor gene expression in human breast cancer. J Mammary Gland Biol Neoplasia 1998;3:85-94.
3. McDonnell DP, Norris JD. Connections and regulation of the human estrogen receptor. Science 2002;296:1642-1644.
4. Smith CL. Cross-talk between peptide growth factor and estrogen receptor signaling pathways. Biol Reprod 1998;58:627-632.
5. Driggers PH, Segars JH. Estrogen action and cytoplasmic signaling pathways. Part II: the role of growth factors and phosphorylation in estrogen signaling. Trends Endocrinol Metab 2002;13:422-427.
6. Hanstein B, Djahansouzi S, Dall P et al. Insights into the molecular biology of the estrogen receptor define novel therapeutic targets for breast cancer. Eur J Endocrinol 2004;150:243-255.
7. Shaaban AM, O'Neill PA, Davies MP et al. Declining estrogen receptor-beta expression defines malignant progression of human breast neoplasia. Am J Surg Pathol 2003;27:1502-1512.
8. Iwase H. Molecular action of the estrogen receptor and hormone dependency in breast cancer. Breast Cancer 2003;10:89-96.
9. Yang X, Phillips DL, Ferguson AT et al. Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res 2001;61:7025-7029.
10. Lapidus RG, Nass SJ, Butash KA et al. Mapping of ER gene CpG island methylation-specific polymerase chain reaction. Cancer Res 1998;58:2515-2519.
11. Bird AP. CpG-rich islands and the function of DNA methylation. Nature 1986;321:209-213.
12. Ferguson AT, Vertino PM, Spitzner JR et al. Role of estrogen receptor gene demethylation and DNA methyltransferase.DNA adduct formation in 5-aza-2′deoxycytidine-induced cytotoxicity in human breast cancer cells. J Biol Chem 1997;272:32260-32266.
13. Robertson KD. DNA methylation, methyltransferases, and cancer. Oncogene 2001;20:3139-3155.
14. Belinsky SA, Nikula KJ, Palmisano WA et al. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci U S A 1998;95:11891-11896.
15. Nuovo GJ, Plaia TW, Belinsky SA et al. In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis. Proc Natl Acad Sci U S A 1999;96:12754-12759.
16. Costello JF, Fruhwald MC, Smiraglia DJ et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 2000;24:132-138.
17. Ling Y, Sankpal UT, Robertson AK et al. Modification of de novo DNA methyltransferase 3a (Dnmt3a) by SUMO-1 modulates its interaction with histone deacetylases (HDACs) and its capacity to repress transcription. Nucleic Acids Res 2004;32:598-610.
18. Rountree MR, Bachman KE, Baylin SB. DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nat Genet 2000;25:269-277.
19. Zhu WG, Otterson GA. The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. Curr Med Chem Anti-Canc Agents 2003;3:187-199.
20. Robertson KD, Ait-Si-Ali S, Yokochi T et al. DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nat Genet 2000;25:338-342.
21. Dobosy JR, Selker EU. Emerging connections between DNA methylation and histone acetylation. Cell Mol Life Sci 2001;58:721-727.
22. Fuks F, Burgers WA, Godin N et al. Dnmt3a binds deacetylases and is recruited by a sequence-specific repressor to silence transcription. EMBO J 2001;20:2536-2544.
23. Ballestar E, Paz MF, Valle L et al. Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer. EMBO J 2003;22:6335-6345.
24. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002;16:6-21.
25. Nan X, Ng HH, Johnson CA et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998;393:386-389.
26. Meehan RR, Lewis JD, McKay S et al. Identification of a mammalian protein that binds specifically to DNA containing methylated CpGs. Cell 1989;58:499-507.
27. Jones PL, Veenstra GJ, Wade PA et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 1998;19:187-191.
28. Fujita N, Watanabe S, Ichimura T et al. Methyl-CpG binding domain 1 (MBD1) interacts with the Suv39h1-HP1 heterochromatic complex for DNA methylation-based transcriptional repression. J Biol Chem 2003;278:24132-24138.
29. El-Osta A, Wolffe AP. DNA methylation and histone deacetylation in the control of gene expression: basic biochemistry to human development and disease. Gene Expr 2000;9:63-75.
30. Nan X, Campoy FJ, Bird A. MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell 1997;88:471-481.
31. Lewis JD, Meehan RR, Henzel WJ et al. Purification, sequence, and cellular localization of a novel chromosomal protein that binds to methylated DNA. Cell 1992;69:905-914.
32. Fuks F, Hurd PJ, Wolf D et al. The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation. J Biol Chem 2003;278:4035-4040.
33. Kouzarides T. Histone methylation in transcriptional control. Curr Opin Genet Dev 2002;12:198-209.
34. Vaute O, Nicolas E, Vandel L et al. Functional and physical interaction between the histone methyl transferase Suv39H1 and histone deacetylases. Nucleic Acids Res 2002;30:475-481.
35. Rea S, Eisenhaber F, O'Carroll D et al. Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature 2000;406:593-599.
36. Tamaru H, Selker EU. A histone H3 methyltransferase controls DNA methylation in Neurospora crassa. Nature 2001;414:277-283.
37. Jackson JP, Lindroth AM, Cao X et al. Control of CpNpG DNA methylation by the KRYPTONITE histone H3 methyltransferase. Nature 2002;416:556-560.
38. Espada J, Ballestar E, Fraga MF et al. Human DNA methyltransferase 1 is required for maintenance of the histone H3 modification pattern. J Biol Chem 2004;279:37175-37184.
39. Fuks F, Hurd PJ, Deplus R et al. The DNA methyltransferases associate with HP1 and the SUV39H1 histone methyltransferase. Nucleic Acids Res 2003;31:2305-2312.
40. Nielsen SJ, Schneider R, Bauer UM et al. Rb targets histone H3 methylation and HP1 to promoters. Nature 2001;412:561-565.
41. Vandel L, Nicolas E, Vaute O et al. Transcriptional repression by the retinoblastoma protein through the recruitment of a histone methyltransferase. Mol Cell Biol 2001;21:6484-6494.
42. Lachner M, O'Carroll D, Rea S et al. Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins. Nature 2001;410:116-120.
43. Bannister AJ, Zegerman P, Partridge JF et al. Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain. Nature 2001;410:120-124.
44. Ferreira R, Magnaghi-Jaulin L, Robin P et al. The three members of the pocket proteins family share the ability to repress E2F activity through recruitment of a histone deacetylase. Proc Natl Acad Sci U S A 1998;95:10493-10498.
45. Brehm A, Miska EA, McCance DJ et al. Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature 1998;391:597-601.
46. Siddiqui H, Solomon DA, Gunawardena RW et al. Histone deacetylation of RB-responsive promoters: requisite for specific gene repression but dispensable for cell cycle inhibition. Mol Cell Biol 2003;23:7719-7731.
47. Mutskov V, Felsenfeld G. Silencing of transgene transcription precedes methylation of promoter DNA and histone H3 lysine 9. EMBO J 2004;23:138-149.
48. Esteller M, Corn PG, Baylin SB et al. A gene hypermethylation profile of human cancer. Cancer Res 2001;61:3225-3229.
49. Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 2002;21:5427-5440.
50. Hortobagyi GN. Treatment of breast cancer. N Engl J Med 1998;339:974-984.
51. Weigel RJ, deConinck EC. Transcriptional control of estrogen receptor in estrogen receptor-negative breast carcinoma. Cancer Res 1993;53:3472-3474.
52. Ferguson AT, Lapidus RG, Davidson NE. Demethylation of the progesterone receptor CpG island is not required for progesterone receptor gene expression. Oncogene 1998;17:577-583.
53. Yang X, Ferguson AT, Nass SJ et al. Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition. Cancer Res 2000;60:6890-6894.
54. Yan L, Nass SJ, Smith D et al. Specific inhibition of DNMT1 by antisense oligonucleotides induces re-expression of estrogen receptor-alpha (ER) in ER-negative human breast cancer cell lines. Cancer Biol Ther 2003;2:552-556.
55. Robert MF, Morin S, Beaulieu N et al. DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat Genet 2003;33:61-65.
56. Paz MF, Wei S, Cigudosa JC et al. Genetic unmasking of epigenetically silenced tumor suppressor genes in colon cancer cells deficient in DNA methyltransferases. Hum Mol Genet 2003;12:2209-2219.
57. Rhee I, Bachman KE, Park BH et al. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 2002;416:552-556.
58. Kawai H, Li H, Avraham S et al. Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor alpha. Int J Cancer 2003;107:353-358.
59. Keen JC, Yan L, Mack KM et al. A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2′-deoxycytidine. Breast Cancer Res Treat 2003;81:177-186.
60. Angeloni SV, Martin MB, Garcia-Morales P et al. Regulation of estrogen receptor-alpha expression by the tumor suppressor gene p53 in MCF-7 cells. J Endocrinol 2004;180:497-504.
61. Martin MB, Angeloni SV, Garcia-Morales P et al. Regulation of estrogen receptor-alpha expression in MCF-7 cells by taxol. J Endocrinol 2004;180:487-496.
62. Macaluso M, Cinti C, Russo G et al. pRb2/p130-E2F4/5-HDAC1-SUV39H1-p300 and pRb2/p130-E2F4/5-HDAC1-SUV39H1-DNMT1 multimolecular complexes mediate the transcription of estrogen receptor-alpha in breast cancer. Oncogene 2003;22:3511-3517.
63. Marks PA. The mechanism of the anti-tumor activity of the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA). Cell Cycle 2004;3:534-535.
64. Bouchain G, Leit S, Frechette S et al. Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors. J Med Chem 2003;46:820-830.
65. Bouchain G, Delorme D. Novel hydroxamate and anilide derivatives as potent histone deacetylase inhibitors: synthesis and antiproliferative evaluation. Curr Med Chem 2003;10:2359-2372.
66. Marks PA, Richon VM, Kelly WK et al. Histone deacetylase inhibitors: development as cancer therapy. Novartis Found Symp 2004;259:269-281, discussion 281-288.
67. Koeller KM, Haggarty SJ, Perkins BD et al. Chemical genetic modifier screens: small molecule trichostatin suppressors as probes of intracellular histone and tubulin acetylation. Chem Biol 2003;10:397-410.
68. Munster PN, Troso-Sandoval T, Rosen N et al. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res 2001;61:8492-8497.
69. Said TK, Moraes RC, Sinha R et al. Mechanisms of suberoylanilide hydroxamic acid inhibition of mammary cell growth. Breast Cancer Res 2001;3:122-133.
70. Castro-Galache MD, Ferragut JA, Barbera VM et al. Susceptibility of multidrug resistance tumor cells to apoptosis induction by histone deacetylase inhibitors. Int J Cancer 2003;104:579-586.
71. Marchion DC, Bicaku E, Daud AI et al. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. J Cell Biochem 2004;92:223-237.